Autoimmune Diseases  >>  Stelara (ustekinumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stelara (ustekinumab) / J&J
NCT00207727: A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis

Completed
2
249
US
CNTO 1275
Centocor, Inc., Centocor BV
Multiple Sclerosis
03/06
08/06
NCT01645280 / 2011-001122-18: A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Completed
2
274
US, Europe, RoW
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Janssen Research & Development, LLC
Arthritis, Rheumatoid
12/13
05/14
NCT02204397: Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis

Completed
2
5
Canada
INGAP Peptide, Ustekinumab, INGAP Peptide, Ustekinumab (Stelara)
Jewish General Hospital
Type 1 Diabetes Mellitus
03/17
03/17

Download Options